We present a single-center cohort of 9 advanced EGFR-amplified high-grade gliomas treated with the antibody-drug conjugate (ADC), Depatuxizumab Mafodotin (Depatux-M, ABT-414). The gene discussed is EGFR; the disease is central nervous system cancer.